Is LNSR or CNXU more profitable?

LENSAR has a net margin of 50.94% compared to Conexeu Sciences' net margin of 0.00%. Conexeu Sciences' return on equity of 0.00% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 50.94% -183.19% 42.26% Conexeu Sciences N/A N/A N/A

Does the media favor LNSR or CNXU?

In the previous week, Conexeu Sciences had 3 more articles in the media than LENSAR. MarketBeat recorded 4 mentions for Conexeu Sciences and 1 mentions for LENSAR. LENSAR's average media sentiment score of 1.90 beat Conexeu Sciences' score of 0.10 indicating that LENSAR is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Conexeu Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, LNSR or PROF?

LENSAR has higher revenue and earnings than Profound Medical. LENSAR is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.22 -$34.28M -$0.58 N/A Profound Medical $16.10M 15.46 -$42.57M -$1.24 N/A

Is LNSR or PROF more profitable?

LENSAR has a net margin of 50.94% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 50.94% -183.19% 42.26% Profound Medical -206.76% -78.88% -64.06%

Does the media prefer LNSR or PROF?

In the previous week, Profound Medical had 5 more articles in the media than LENSAR. MarketBeat recorded 6 mentions for Profound Medical and 1 mentions for LENSAR. LENSAR's average media sentiment score of 1.90 beat Profound Medical's score of 0.49 indicating that LENSAR is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Profound Medical 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LNSR or TLSI?

In the previous week, LENSAR and LENSAR both had 1 articles in the media. LENSAR's average media sentiment score of 1.90 beat TriSalus Life Sciences' score of 0.00 indicating that LENSAR is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, LNSR or OBIO?

LENSAR has higher revenue and earnings than Orchestra BioMed. LENSAR is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.22 -$34.28M -$0.58 N/A Orchestra BioMed $33.48M 6.58 -$52.70M -$0.97 N/A

Is LNSR or OBIO more profitable?

LENSAR has a net margin of 50.94% compared to Orchestra BioMed's net margin of -166.96%. Orchestra BioMed's return on equity of -157.46% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 50.94% -183.19% 42.26% Orchestra BioMed -166.96% -157.46% -60.18%

Does the media prefer LNSR or OBIO?

In the previous week, Orchestra BioMed had 1 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for Orchestra BioMed and 1 mentions for LENSAR. Orchestra BioMed's average media sentiment score of 1.94 beat LENSAR's score of 1.90 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is SMTI or LNSR more profitable?

LENSAR has a net margin of 50.94% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -31.23% -3.19% -0.56% LENSAR 50.94% -183.19% 42.26%

Does the media refer more to SMTI or LNSR?

In the previous week, Sanara MedTech and Sanara MedTech both had 1 articles in the media. LENSAR's average media sentiment score of 1.90 beat Sanara MedTech's score of 1.02 indicating that LENSAR is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENSAR 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

LENSAR (LNSR) Competitors

$5.80 0.00 (0.00%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$5.80 0.00 (-0.09%)

As of 07/17/2026 06:25 PM Eastern

Compare

LNSR vs. CNXU, PROF, TLSI, OBIO, and SMTI

Should you buy LENSAR stock or one of its competitors? MarketBeat compares LENSAR with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENSAR include Conexeu Sciences (CNXU), Profound Medical (PROF), TriSalus Life Sciences (TLSI), Orchestra BioMed (OBIO), and Sanara MedTech (SMTI). These companies are all part of the "medical equipment" industry.

How does LENSAR compare to Conexeu Sciences?

LENSAR (NASDAQ:LNSR) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Conexeu Sciences has lower revenue, but higher earnings than LENSAR. Conexeu Sciences is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.22	-$34.28M	-$0.58	N/A
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A

In the previous week, Conexeu Sciences had 3 more articles in the media than LENSAR. MarketBeat recorded 4 mentions for Conexeu Sciences and 1 mentions for LENSAR. LENSAR's average media sentiment score of 1.90 beat Conexeu Sciences' score of 0.10 indicating that LENSAR is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Conexeu Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LENSAR presently has a consensus price target of $10.00, indicating a potential upside of 72.41%. Conexeu Sciences has a consensus price target of $20.00, indicating a potential upside of 103.46%. Given Conexeu Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Conexeu Sciences is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

LENSAR has a net margin of 50.94% compared to Conexeu Sciences' net margin of 0.00%. Conexeu Sciences' return on equity of 0.00% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
Conexeu Sciences	N/A	N/A	N/A

40.2% of LENSAR shares are held by institutional investors. 65.8% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

LENSAR beats Conexeu Sciences on 8 of the 13 factors compared between the two stocks.

How does LENSAR compare to Profound Medical?

LENSAR (NASDAQ:LNSR) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

LENSAR presently has a consensus target price of $10.00, indicating a potential upside of 72.41%. Profound Medical has a consensus target price of $12.00, indicating a potential upside of 75.18%. Given Profound Medical's higher probable upside, analysts clearly believe Profound Medical is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

LENSAR has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

40.2% of LENSAR shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 65.8% of LENSAR shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Profound Medical had 5 more articles in the media than LENSAR. MarketBeat recorded 6 mentions for Profound Medical and 1 mentions for LENSAR. LENSAR's average media sentiment score of 1.90 beat Profound Medical's score of 0.49 indicating that LENSAR is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Profound Medical	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LENSAR has a net margin of 50.94% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
Profound Medical	-206.76%	-78.88%	-64.06%

LENSAR has higher revenue and earnings than Profound Medical. LENSAR is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.22	-$34.28M	-$0.58	N/A
Profound Medical	$16.10M	15.46	-$42.57M	-$1.24	N/A

Summary

LENSAR beats Profound Medical on 10 of the 16 factors compared between the two stocks.

How does LENSAR compare to TriSalus Life Sciences?

LENSAR (NASDAQ:LNSR) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, LENSAR and LENSAR both had 1 articles in the media. LENSAR's average media sentiment score of 1.90 beat TriSalus Life Sciences' score of 0.00 indicating that LENSAR is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.2% of LENSAR shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 65.8% of LENSAR shares are held by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

LENSAR has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

LENSAR presently has a consensus price target of $10.00, indicating a potential upside of 72.41%. TriSalus Life Sciences has a consensus price target of $7.50, indicating a potential upside of 74.83%. Given TriSalus Life Sciences' higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

LENSAR has a net margin of 50.94% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

LENSAR has higher revenue and earnings than TriSalus Life Sciences. LENSAR is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.22	-$34.28M	-$0.58	N/A
TriSalus Life Sciences	$45.15M	5.84	-$39.23M	-$1.41	N/A

Summary

LENSAR beats TriSalus Life Sciences on 10 of the 14 factors compared between the two stocks.

How does LENSAR compare to Orchestra BioMed?

LENSAR (NASDAQ:LNSR) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

LENSAR has a net margin of 50.94% compared to Orchestra BioMed's net margin of -166.96%. Orchestra BioMed's return on equity of -157.46% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	50.94%	-183.19%	42.26%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

LENSAR has higher revenue and earnings than Orchestra BioMed. LENSAR is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.22	-$34.28M	-$0.58	N/A
Orchestra BioMed	$33.48M	6.58	-$52.70M	-$0.97	N/A

LENSAR has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

LENSAR currently has a consensus target price of $10.00, indicating a potential upside of 72.41%. Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 269.57%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Orchestra BioMed had 1 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for Orchestra BioMed and 1 mentions for LENSAR. Orchestra BioMed's average media sentiment score of 1.94 beat LENSAR's score of 1.90 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

40.2% of LENSAR shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 65.8% of LENSAR shares are held by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Orchestra BioMed beats LENSAR on 9 of the 16 factors compared between the two stocks.

How does LENSAR compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Sanara MedTech and Sanara MedTech both had 1 articles in the media. LENSAR's average media sentiment score of 1.90 beat Sanara MedTech's score of 1.02 indicating that LENSAR is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENSAR	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Sanara MedTech has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, LENSAR has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by company insiders. Comparatively, 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

LENSAR has lower revenue, but higher earnings than Sanara MedTech. LENSAR is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	2.22	-$37.56M	-$3.77	N/A
LENSAR	$58.44M	1.22	-$34.28M	-$0.58	N/A

LENSAR has a net margin of 50.94% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
LENSAR	50.94%	-183.19%	42.26%

Sanara MedTech currently has a consensus price target of $34.00, suggesting a potential upside of 36.00%. LENSAR has a consensus price target of $10.00, suggesting a potential upside of 72.41%. Given LENSAR's higher probable upside, analysts clearly believe LENSAR is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

LENSAR beats Sanara MedTech on 8 of the 15 factors compared between the two stocks.

Get LENSAR News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNSR vs. The Competition

Export

Metric	LENSAR	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$71.22M	$7.28B	$6.86B	$12.27B
Dividend Yield	N/A	1.32%	2.67%	9.36%
P/E Ratio	-10.00	50.09	27.23	23.92
Price / Sales	1.22	83.01	581.44	113.62
Price / Cash	N/A	26.91	29.05	48.09
Price / Book	-2.66	7.03	10.62	6.18
Net Income	-$34.28M	$162.27M	$3.59B	$331.89M
7 Day Performance	-0.34%	-1.32%	-1.06%	-1.28%
1 Month Performance	1.05%	-1.24%	1.63%	-1.36%
1 Year Performance	-55.73%	6.83%	25.61%	17.73%

LENSAR Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNSR LENSAR	2.716 of 5 stars	$5.80 flat	$10.00 +72.4%	-55.7%	$71.22M	$58.44M	N/A	110	Positive News Gap Down
CNXU Conexeu Sciences	2.8585 of 5 stars	$9.50 -8.1%	$20.00 +110.5%	N/A	$276.68M	N/A	N/A	4	Gap Up
PROF Profound Medical	1.6551 of 5 stars	$7.10 -0.7%	$12.00 +69.0%	+21.5%	$259.84M	$16.10M	N/A	150	Positive News
TLSI TriSalus Life Sciences	1.925 of 5 stars	$4.04 -4.5%	$7.50 +85.6%	-6.7%	$259.79M	$45.15M	N/A	106	Positive News
OBIO Orchestra BioMed	4.4893 of 5 stars	$3.69 -3.4%	$13.60 +268.6%	+19.1%	$228.74M	$33.48M	N/A	4	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNSR) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENSAR (LNSR) Competitors

LNSR vs. CNXU, PROF, TLSI, OBIO, and SMTI

How does LENSAR compare to Conexeu Sciences?

Summary

How does LENSAR compare to Profound Medical?

Summary

How does LENSAR compare to TriSalus Life Sciences?

Summary

How does LENSAR compare to Orchestra BioMed?

Summary

How does LENSAR compare to Sanara MedTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENSAR (LNSR) Competitors

LNSR vs. CNXU, PROF, TLSI, OBIO, and SMTI

How does LENSAR compare to Conexeu Sciences?

Which has better earnings & valuation, LNSR or CNXU?

Does the media favor LNSR or CNXU?

Do analysts recommend LNSR or CNXU?

Is LNSR or CNXU more profitable?

Do insiders & institutionals believe in LNSR or CNXU?

Summary

How does LENSAR compare to Profound Medical?

Do analysts prefer LNSR or PROF?

Which has more volatility and risk, LNSR or PROF?

Do insiders & institutionals believe in LNSR or PROF?

Does the media prefer LNSR or PROF?

Is LNSR or PROF more profitable?

Which has better earnings & valuation, LNSR or PROF?

Summary

How does LENSAR compare to TriSalus Life Sciences?

Does the media prefer LNSR or TLSI?

Do insiders and institutionals believe in LNSR or TLSI?

Which has more risk and volatility, LNSR or TLSI?

Do analysts rate LNSR or TLSI?

Is LNSR or TLSI more profitable?

Which has better earnings and valuation, LNSR or TLSI?

Summary

How does LENSAR compare to Orchestra BioMed?

Is LNSR or OBIO more profitable?

Which has higher earnings & valuation, LNSR or OBIO?

Which has more risk & volatility, LNSR or OBIO?

Do analysts rate LNSR or OBIO?

Does the media prefer LNSR or OBIO?

Do insiders & institutionals believe in LNSR or OBIO?

Summary

How does LENSAR compare to Sanara MedTech?

Does the media refer more to SMTI or LNSR?

Which has more volatility & risk, SMTI or LNSR?

Do institutionals and insiders have more ownership in SMTI or LNSR?

Which has better valuation & earnings, SMTI or LNSR?

Is SMTI or LNSR more profitable?

Do analysts recommend SMTI or LNSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools